Entero Therapeutics Financials
Entero Therapeutics (ENTO) reported $36K in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Entero now looks like a development-stage company whose main operating mechanic is cash burn funded by fresh financing rather than product revenue.
FY2025’s net loss narrowed to-$6.4M and operating cash burn improved to-$5.7M , but near-term liquidity still worsened sharply as the current ratio fell from 3.0x in FY2024 to 0.2x and cash ended at just$900K . That combination suggests the income statement improved faster than the balance sheet’s ability to absorb ongoing burn, so access to funding remained central to operations.
With only
The balance sheet looked stronger on paper than the cash position alone would imply: total equity was
Financial Health Signals
Entero Therapeutics does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Entero Therapeutics scores -6.67, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($4.7M) relative to total liabilities ($19.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Entero Therapeutics passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Entero Therapeutics reported a net loss of $6.4M while operations used $5.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Entero Therapeutics generated $36K in revenue in fiscal year 2025.
Entero Therapeutics's EBITDA was -$6.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 58.2% from the prior year.
Entero Therapeutics reported -$6.4M in net income in fiscal year 2025. This represents an increase of 64.6% from the prior year.
Cash & Balance Sheet
Entero Therapeutics held $900K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Entero Therapeutics's ROE was -25.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Entero Therapeutics invested $925K in research and development in fiscal year 2025. This represents an increase of 2.4% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
ENTO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $36K | N/A | N/A | N/A | N/A | N/A | $0 | $0 | N/A | N/A | N/A |
| Cost of Revenue | N/A | $694K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | -$657K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $925K+2.4% | $904K-82.0% | $5.0M-42.6% | $8.8M-48.4% | $17.0M+188.6% | $5.9M-32.2% | $8.7M+50.4% | $5.8M+140.9% | $2.4M-4.0% | $2.5M+78.5% | $1.4M |
| SG&A Expenses | N/A | $5.5M-62.6% | $14.7M+37.1% | $10.7M-10.4% | $12.0M-34.8% | $18.4M+152.0% | $7.3M+20.3% | $6.1M-18.6% | $7.5M-3.1% | $7.7M+86.1% | $4.1M+24.0% | $3.3M |
| Operating Income | N/A | -$7.1M+54.7% | -$15.6M+0.9% | -$15.8M-24.4% | -$12.7M | N/A | -$26.4M-79.3% | -$14.7M-9.8% | -$13.4M-31.4% | -$10.2M-61.6% | -$6.3M-33.8% | -$4.7M |
| Interest Expense | N/A | N/A | N/A | $22K+41.5% | $16K+41.3% | $11K-99.8% | $5.8M+1246.0% | $434K+326.1% | $102K-88.4% | $875K-85.3% | $5.9M+274.0% | $1.6M |
| Income Tax | N/A | -$399K | N/A | N/A | N/A | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Net Income | N/A | -$6.4M+64.6% | -$18.1M-14.3% | -$15.8M-8.0% | -$14.6M+75.0% | -$58.5M-79.2% | -$32.7M-115.3% | -$15.2M-12.1% | -$13.5M-22.0% | -$11.1M+24.0% | -$14.6M-146.1% | -$5.9M |
| EPS (Diluted) | — | -$4.16 | -$15.99 | -$47.88 | -$416.94+79.0% | -$1988.53 | -$14.68 | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ENTO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $48.6M-43.2% | $85.4M+1140.8% | $6.9M+26.5% | $5.4M-53.9% | $11.8M-8.8% | $12.9M+45.2% | $8.9M+19.2% | $7.5M+36.3% | $5.5M-18.9% | $6.8M+1.0% | $6.7M |
| Current Assets | $2.6M-96.9% | $83.5M+1584.3% | $5.0M+45.2% | $3.4M-63.8% | $9.4M+19.8% | $7.9M+130.9% | $3.4M-29.0% | $4.8M+145.8% | $2.0M-34.1% | $3.0M+43.4% | $2.1M |
| Cash & Equivalents | $900K+450.4% | $163K-95.6% | $3.7M+172.3% | $1.4M-83.5% | $8.2M+36.1% | $6.1M+3348.4% | $176K-84.2% | $1.1M+94.3% | $573K | $0-100.0% | $582K |
| Accounts Receivable | $30K | N/A | N/A | $93K | $0-100.0% | $551K-79.1% | $2.6M-16.9% | $3.2M+187.3% | $1.1M+14.9% | $961K-10.6% | $1.1M |
| Goodwill | $24.1M+1332.1% | $1.7M0.0% | $1.7M0.0% | $1.7M-11.9% | $1.9M-6.9% | $2.1M+8.9% | $1.9M-2.0% | $1.9M-4.5% | $2.0M+14.1% | $1.8M-3.5% | $1.8M |
| Total Liabilities | $19.7M-77.9% | $89.3M+2621.9% | $3.3M+21.6% | $2.7M-86.2% | $19.6M+26.0% | $15.6M+263.2% | $4.3M+43.1% | $3.0M-21.6% | $3.8M+7.9% | $3.5M-65.7% | $10.3M |
| Current Liabilities | $15.2M-45.0% | $27.5M+779.1% | $3.1M+26.2% | $2.5M-79.8% | $12.3M-20.9% | $15.5M+262.7% | $4.3M+43.1% | $3.0M+20.8% | $2.5M+5.9% | $2.3M-73.4% | $8.8M |
| Total Equity | $24.9M+743.4% | -$3.9M-207.6% | $3.6M+31.4% | $2.7M+135.1% | -$7.8M-196.2% | -$2.6M-157.2% | $4.6M+3.2% | $4.5M+169.4% | $1.7M-48.3% | $3.2M+188.5% | -$3.6M |
| Retained Earnings | -$208.8M-3.2% | -$202.4M-9.8% | -$184.3M-9.4% | -$168.5M-9.5% | -$153.9M-61.4% | -$95.4M-52.1% | -$62.7M-31.9% | -$47.5M-39.8% | -$34.0M-48.5% | -$22.9M-175.9% | -$8.3M |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
ENTO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.7M | -$5.7M+38.1% | -$9.2M+25.5% | -$12.4M+44.6% | -$22.3M+30.8% | -$32.3M-187.7% | -$11.2M+20.0% | -$14.0M-29.1% | -$10.9M-51.3% | -$7.2M-58.4% | -$4.5M-8.7% | -$4.2M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | $69K+1567.6% | $4K-82.7% | $24K-56.6% | $55K+72.4% | $32K+160.4% | $12K-49.3% | $24K |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | -$32.4M-188.2% | -$11.2M+20.1% | -$14.1M-28.7% | -$10.9M-51.4% | -$7.2M-58.7% | -$4.5M-8.4% | -$4.2M |
| Investing Cash Flow | N/A | $323K+266.9% | $88K+117.6% | -$500K | N/A | -$10.3M-11914.0% | $87K+462.5% | -$24K+92.1% | -$305K-849.6% | -$32K-160.4% | -$12K+49.3% | -$24K |
| Financing Cash Flow | $6.6M | $5.9M+5.5% | $5.6M-63.3% | $15.2M-3.3% | $15.7M-64.8% | $44.8M+162.6% | $17.0M+29.7% | $13.1M+12.2% | $11.7M+94.8% | $6.0M+4.6% | $5.7M+22.8% | $4.7M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ENTO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -1813.6% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -19540.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -17634.4% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -25.6% | N/A | -438.4%+95.1pp | -533.5% | N/A | N/A | -328.7%-26.2pp | -302.5%+365.7pp | -668.2%-214.1pp | -454.1% | N/A |
| Return on Assets | -13.2%+8.0pp | -21.1%+208.3pp | -229.5%+39.5pp | -268.9%+227.6pp | -496.5%-243.7pp | -252.8%-82.3pp | -170.5%+10.7pp | -181.2%+21.3pp | -202.5%+13.5pp | -216.0%-127.3pp | -88.7% |
| Current Ratio | 0.17-2.9x | 3.03+1.4x | 1.58+0.2x | 1.37+0.6x | 0.77+0.3x | 0.51-0.3x | 0.80-0.8x | 1.60+0.8x | 0.79-0.5x | 1.27+1.0x | 0.23 |
| Debt-to-Equity | 0.79 | N/A | 0.91-0.1x | 0.98 | N/A | N/A | 0.93+0.3x | 0.67-1.6x | 2.30+1.2x | 1.10 | N/A |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin.
Note: The current ratio is below 1.0 (0.17), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Entero Therapeutics Ranks
Frequently Asked Questions
What is Entero Therapeutics's annual revenue?
Entero Therapeutics (ENTO) reported $36K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Entero Therapeutics profitable?
No, Entero Therapeutics (ENTO) reported a net income of -$6.4M in fiscal year 2025.
What is Entero Therapeutics's EBITDA?
Entero Therapeutics (ENTO) had EBITDA of -$6.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Entero Therapeutics's return on equity (ROE)?
Entero Therapeutics (ENTO) has a return on equity of -25.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Entero Therapeutics's operating cash flow?
Entero Therapeutics (ENTO) recorded an outflow of $5.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Entero Therapeutics's total assets?
Entero Therapeutics (ENTO) had $48.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Entero Therapeutics spend on research and development?
Entero Therapeutics (ENTO) invested $925K in research and development during fiscal year 2025.
What is Entero Therapeutics's current ratio?
Entero Therapeutics (ENTO) had a current ratio of 0.17 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Entero Therapeutics's debt-to-equity ratio?
Entero Therapeutics (ENTO) had a debt-to-equity ratio of 0.79 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Entero Therapeutics's return on assets (ROA)?
Entero Therapeutics (ENTO) had a return on assets of -13.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Entero Therapeutics's cash runway?
Based on fiscal year 2025 data, Entero Therapeutics (ENTO) had $900K in cash against an annual operating cash burn of $5.7M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Entero Therapeutics's Altman Z-Score?
Entero Therapeutics (ENTO) has an Altman Z-Score of -6.67, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Entero Therapeutics's Piotroski F-Score?
Entero Therapeutics (ENTO) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Entero Therapeutics's earnings high quality?
Entero Therapeutics (ENTO) reported a net loss of $6.4M while operations used $5.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.